Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment.

Int J Gen Med · 2021 · PMC8866991 · PMID 35221710

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As exhibited in Figure 5 , patients with GSTP1-H showed a trend of worse OS compared with those with GSTP1-L [median OS: 9.2 (95% CI: 3.01–15.39) months vs 16.3 (95% CI: 12.42–20.18) months], although the difference was not statistically significant (χ 2 =3.247, P =0.072).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.